Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Catherine
FLIGHT, NCT04446182: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Jul 2022 - Dec 2022 : Data from part-1 of P2 FLIGHT trial for cGVHD	Terminated	2	3	US	Itacitinib, INCB039110, Extracorporeal Photopheresis (ECP), ECP	University of Utah, Incyte Corporation	Chronic Graft-versus-host-disease	03/22	01/23
NCT03298815: Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)	Completed	1/2	15	US	Amniotic Fluid Eye Drops (AFED), Saline Solution	University of Utah	Ocular Graft Versus Host Disease	12/22	02/23
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation	Recruiting	1	40	US	Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191	Jasper Therapeutics, Inc.	MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML	10/23	12/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
NCT06641310: Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)	Not yet recruiting	N/A	32	US	Endurance Exercise Therapy	University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)	Familial Adenomatous Polyposis	03/27	03/27
San, Htu
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Catherine
FLIGHT, NCT04446182: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Jul 2022 - Dec 2022 : Data from part-1 of P2 FLIGHT trial for cGVHD	Terminated	2	3	US	Itacitinib, INCB039110, Extracorporeal Photopheresis (ECP), ECP	University of Utah, Incyte Corporation	Chronic Graft-versus-host-disease	03/22	01/23
NCT03298815: Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)	Completed	1/2	15	US	Amniotic Fluid Eye Drops (AFED), Saline Solution	University of Utah	Ocular Graft Versus Host Disease	12/22	02/23
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation	Recruiting	1	40	US	Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191	Jasper Therapeutics, Inc.	MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML	10/23	12/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
NCT06641310: Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)	Not yet recruiting	N/A	32	US	Endurance Exercise Therapy	University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)	Familial Adenomatous Polyposis	03/27	03/27
San, Htu
No trials found